The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells.
Open accessAbstract
On the basis of preceding studies showing that tumor-induced, T cell-mediated immunosuppression serves as an obstacle to adoptive immunotherapy of the Meth A fibrosarcoma, it was predicted that cyclophosphamide treatment of tumor bearers would remove this obstacle and allow passively transferred immune T cells to cause tumor regression. It was found that infusion of immune spleen cells alone had no effect on tumor growth, and cyclophosphamide alone caused a temporary halt in tumor progression. In contrast, combination therapy consisting of intravenous injection of 100 mg/kg of cyclophosphamide followed 1 h later by intravenous infusion of tumor-immune spleen cells caused small, as well as large tumors, to completely and permanently regress. Tumor regression caused by combination therapy was completely inhibited by intravenous infusion of splenic T cells from donors with established tumors, but not by spleen cells from normal donors. These suppressor T cells were eliminated from the spleen by treating the tumor-bearing donors with 100 mg/kg of cyclophosphamide. Immune T cells, in contrast, were resistant to this dose of cyclophosphamide. These results show that failure of intravenously-infused, tumor-sensitized T cells to cause regression of the Meth A fibrosarcoma growing in its syngeneic or semi-syngeneic host is caused by the presence of a tumor-induced population of cyclophosphamide-sensitive suppressor T cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Berendt, M. J., & North, R. J. (1980) · The Journal of experimental medicine · doi:10.1084/jem.151.1.69 · Cited by 369
Self-citationRollinghoff, M., Starzinski-Powitz, A., Pfizenmaier, K., & Wagner, H. (1977) · The Journal of Experimental Medicine · doi:10.1084/jem.145.2.455 · Cited by 335
Greenberg, P. D., Cheever, M. A., & Fefer, A. (1981) · The Journal of experimental medicine · doi:10.1084/jem.154.3.952 · Cited by 312
Passive Immunotherapy of Cancer in Animals and Man
(1977) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60637-5 · Cited by 243
Glaser, M. (1979) · The Journal of Experimental Medicine · doi:10.1084/jem.149.3.774 · Cited by 119
Mitsuyoshi, G. O. T. O., Mitsuoka, A., Sugiyama, M., et al. (1981) · The Journal of Experimental Medicine · doi:10.1084/jem.154.1.204 · Cited by 53
Mills, C. D., North, R. J., & Dye, E. S. (1981) · The Journal of Experimental Medicine · doi:10.1084/jem.154.3.621 · Cited by 38
Self-citation
Cited by
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., et al. (2002) · Science · doi:10.1126/science.1076514 · Cited by 2,823
Photodynamic therapy and anti-tumour immunity
Castano, A. P., Mroz, P., & Hamblin, M. R. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1894 · Cited by 2,676
Immunological aspects of cancer chemotherapy
Zitvogel, L., Apetoh, L., Ghiringhelli, F., & Kroemer, G. (2008) · Nature Reviews Immunology · doi:10.1038/nri2216 · Cited by 1,712
Adoptive immunotherapy for cancer: harnessing the T cell response
Restifo, N. P., Dudley, M. E., & Rosenberg, S. A. (2012) · Nature Reviews Immunology · doi:10.1038/nri3191 · Cited by 1,688
“Fakat tümör mikroçevresindeki immünsüpresif hücresel elementler uzun olarak gözlemlenmiştir (99-101).”
Dudley, M. E., Wunderlich, J. R., Yang, J. C., Sherry, R. M., Topalian, S. L., Restifo, N. P., Royal, R. E., Kammula, U., White, D. E., Mavroukakis, S. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.240 · Cited by 1,639
Kochenderfer, J. N., Dudley, M. E., Kassim, S. H., Somerville, R. P. T., Carpenter, R. O., Stetler-Stevenson, M., Yang, J. C., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2025 · Cited by 1,595
Shimizu, J., Yamazaki, S., & Sakaguchi, S. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.10.5211 · Cited by 1,491
Brentjens, R. J., Rivière, I., Park, J. H., Davila, M. L., Wang, X., Stefanski, J., Taylor, C., Yeh, R., Bartido, S., Borquez-Ojeda, O., et al. (2011) · Blood · doi:10.1182/blood-2011-04-348540 · Cited by 1,286
Gattinoni, L., Finkelstein, S. E., Klebanoff, C. A., Antony, P. A., Palmer, D. C., Spiess, P. J., Hwang, L. N., Yu, Z., Wrzesinski, C., Heimann, D. M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050732 · Cited by 1,061
Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management
Brudno, J. N., & Kochenderfer, J. N. (2019) · Blood Reviews · doi:10.1016/j.blre.2018.11.002 · Cited by 899
Ghiringhelli, F., Larmonier, N., Schmitt, E., Parcellier, A., Cathelin, D., Garrido, C., Chauffert, B., Solary, E., Bonnotte, B., & Martin, F. (2004) · European Journal of Immunology · doi:10.1002/eji.200324181 · Cited by 880
Adoptive immunotherapy for cancer: building on success
Gattinoni, L., Powell, D. J., Rosenberg, S. A., & Restifo, N. P. (2006) · Nature Reviews Immunology · doi:10.1038/nri1842 · Cited by 845
Brudno, J. N., Maric, I., Hartman, S. D., Rose, J. J., Wang, M., Lam, N., Stetler-Stevenson, M., Salem, D., Yuan, C., Pavletic, S., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.8084 · Cited by 781
Ali, S. A., Shi, V., Maric, I., Wang, M., Stroncek, D. F., Rose, J. J., Brudno, J. N., Stetler-Stevenson, M., Feldman, S. A., Hansen, B. G., et al. (2016) · Blood · doi:10.1182/blood-2016-04-711903 · Cited by 757
Induction of antigen-specific T cell anergy: An early event in the course of tumor progression
Staveley-O’Carroll, K., Sotomayor, E., Montgomery, J., Borrello, I., Hwang, L., Fein, S., Pardoll, D., & Levitsky, H. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.3.1178 · Cited by 704
Mulé, J. J., Shu, S., Schwarz, S. L., & Rosenberg, S. A. (1984) · Science · doi:10.1126/science.6332379 · Cited by 688
Mechanisms of Immune Evasion by Tumors
Drake, C. G., Jaffee, E., & Pardoll, D. M. (2006) · Advances in Immunology · doi:10.1016/s0065-2776(06)90002-9 · Cited by 688
Down-Regulation of the Antitumor Immune Response
(1985) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60265-1 · Cited by 682
Adoptive-cell-transfer therapy for the treatment of patients with cancer
Dudley, M. E., & Rosenberg, S. A. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1167 · Cited by 660
Greenberg, P. D. (1991) · Advances in Immunology · doi:10.1016/s0065-2776(08)60778-6 · Cited by 603
Paulos, C. M., Wrzesinski, C., Kaiser, Hinrichs, C. S., Chieppa, M., Cassard, L., Palmer, D. C., Boni, A., Muranski, P., Yu, Z., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32205 · Cited by 586
The anticancer immune response: indispensable for therapeutic success?
Zitvogel, L., Apetoh, L., Ghiringhelli, F., André, F., Tesniere, A., & Kroemer, G. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35180 · Cited by 573
Kochenderfer, J. N., Somerville, R. P. T., Lu, T., Shi, V., Bot, A., Rossi, J., Xue, A., Goff, S. L., Yang, J. C., Sherry, R. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.3024 · Cited by 569
Concomitant Tumor Immunity to a Poorly Immunogenic Melanoma Is Prevented by Regulatory T Cells
Turk, M. J., Guevara-Patiño, J. A., Rizzuto, G. A., Engelhorn, M. E., & Houghton, A. N. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20041130 · Cited by 540
Till, B. G., Jensen, M. C., Wang, J., Qian, X., Gopal, A. K., Maloney, D. G., Lindgren, C. G., Lin, Y., Pagel, J. M., Budde, L. E., et al. (2012) · Blood · doi:10.1182/blood-2011-10-387969 · Cited by 529
Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors
Kochenderfer, J. N., & Rosenberg, S. A. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.46 · Cited by 451
Tan, M. C. B., Goedegebuure, P. S., Belt, B. A., Flaherty, B., Sankpal, N., Gillanders, W. E., Eberlein, T. J., Hsieh, C.-S., & Linehan, D. C. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.3.1746 · Cited by 450
Chemophototherapy: An Emerging Treatment Option for Solid Tumors
Luo, D., Carter, K. A., Miranda, D., & Lovell, J. F. (2017) · Advanced Science · doi:10.1002/advs.201600106 · Cited by 436
Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer
Drake, C. G., Lipson, E. J., & Brahmer, J. R. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.208 · Cited by 422
Regulatory T-cell inhibition versus depletion: the right choice in cancer immunotherapy
Colombo, M. P., & Piconese, S. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2250 · Cited by 407
Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response
Ercolini, A. M., Ladle, B. H., Manning, E. A., Pfannenstiel, L. W., Armstrong, T. D., Machiels, J.-P. H., Bieler, J. G., Emens, L. A., Reilly, R. T., & Jaffee, E. M. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20042167 · Cited by 399
Kochenderfer, J. N., Yu, Z., Frasheri, D., Restifo, N. P., & Rosenberg, S. A. (2010) · Blood · doi:10.1182/blood-2010-01-265041 · Cited by 391
(2010) · Advances in Cancer Research · doi:10.1016/s0065-230x(10)07003-x · Cited by 386
Danna, E. A., Sinha, P., Gilbert, M., Clements, V. K., Pulaski, B. A., & Ostrand-Rosenberg, S. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2646 · Cited by 371
Cellular Constituents of Immune Escape within the Tumor Microenvironment
Kerkar, S. P., & Restifo, N. P. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-4094 · Cited by 370
Mazumder, A., & Rosenberg, S. A. (1984) · The Journal of experimental medicine · doi:10.1084/jem.159.2.495 · Cited by 369
Kanakry, C. G., Ganguly, S., Zahurak, M., Bolaños-Meade, J., Thoburn, C., Perkins, B., Fuchs, E. J., Jones, R. J., Hess, A. D., & Luznik, L. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006960 · Cited by 357
Dudley, M. E., Wunderlich, J. R., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R. M., Marincola, F. M., Leitman, S. F., Seipp, C. A., et al. (2002) · Journal of Immunotherapy · doi:10.1097/00002371-200205000-00007 · Cited by 357
Andersen, R., Donia, M., Ellebaek, E., Borch, T. H., Kongsted, P., Iversen, T. Z., Hölmich, L. R., Hendel, H. W., Met, Ö., Andersen, M. H., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1879 · Cited by 317
Cancer Immunotherapy Using Interleukin-2 and Interleukin-2-Activated Lymphocytes
Rosenberg, S. A., & Lotze, M. T. (1986) · Annual Review of Immunology · doi:10.1146/annurev.iy.04.040186.003341 · Cited by 314
Brudno, J. N., Lam, N., Vanasse, D., Shen, Y.-W., Rose, J. J., Rossi, J., Xue, A., Bot, A., Scholler, N., Mikkilineni, L., et al. (2020) · Nature Medicine · doi:10.1038/s41591-019-0737-3 · Cited by 311
Berd, D., Maguire, H. C., McCue, P., & Mastrangelo, M. J. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.11.1858 · Cited by 300
Greenberg, P. D., Kern, D. E., & Cheever, M. A. (1985) · The Journal of experimental medicine · doi:10.1084/jem.161.5.1122 · Cited by 292
Chinnasamy, D., Yu, Z., Kerkar, S. P., Zhang, L., Morgan, R. A., Restifo, N. P., & Rosenberg, S. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3050 · Cited by 277
Therapeutic cancer vaccines: Are we there yet?
Klebanoff, C. A., Acquavella, N., Yu, Z., & Restifo, N. P. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00979.x · Cited by 271
Dafni, U., Michielin, O., Lluesma, S. M., Tsourti, Z., Polydoropoulou, V, Karlis, D., Besser, M. J., Haanen, J., Svane, I. M., Ohashi, P. S., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz398 · Cited by 263
Chinnasamy, D., Yu, Z., Theoret, M. R., Zhao, Y., Shrimali, R. K., Morgan, R. A., Feldman, S. A., Restifo, N. P., & Rosenberg, S. A. (2010) · Journal of Clinical Investigation · doi:10.1172/jci43490 · Cited by 253
North, R. J., & Bursuker, I. (1984) · The Journal of experimental medicine · doi:10.1084/jem.159.5.1295 · Cited by 253
Self-citationMénard, C., Blay, J.-Y., Borg, C., Michiels, S., Ghiringhelli, F., Robert, C., Nonn, C., Chaput, N., Taïeb, J., Delahaye, N. F., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3807 · Cited by 202
“Other drugs may have side effects that stimulate the immune system, by transient lymphodepletion (7), by the subversion of immunosuppressive mechanisms (33, 35), or by direct or indirect stimulatory effects on immune effectors (36, 37).”
BackgroundPhotodynamic therapy plus low-dose cyclophosphamide generates antitumor immunity in a mouse model
Castano, A. P., Mroz, P., Wu, M. X., & Hamblin, M. R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709256105 · Cited by 201
The Role of Tumor Microenvironment in Cancer Immunotherapy
Frankel, T., Lanfranca, M. P., & Zou, W. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-67577-0_4 · Cited by 173
Lu, Y., Hong, B., Li, H., Zheng, Y., Zhang, M., Wang, S., Qian, J., & Yi, Q. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1317431111 · Cited by 146
Mikkilineni, L., Natrakul, D. A., Lam, N., Manasanch, E. E., Mann, J., Weissler, K. A., Wong, N., Brudno, J. N., Goff, S. L., Yang, J. C., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2023.12.018 · Cited by 16
Metadata
- Authors
- North, R. J.
- Venue
- The Journal of experimental medicine
- Publisher
- Rockefeller University Press
- Published
- 1982-04-01
- Volume
- 155
- Issue
- 4
- Pages
- 1063-1074
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2047203592
- Cited by
- 650
- References
- 7
- FWCI
- 11.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.